Brain natriuretic peptide (BNP), first discovered in porcine brain, is principally produced by the heart. Unlike atrial natriuretic peptide (ANP), BNP is largely derived from the ventricles.

Heart failure (HF) is a leading cause of morbidity and mortality worldwide. Testing for natriuretic peptide markers, such as B-type natriuretic peptide (BNP) or N-terminal proBNP (NT-proBNP), has ...

The inactive N-terminal fragment of pro-brain natriuretic peptide (NT-proBNP) has been linked to ventricular dysfunction in the general population, and is predictive of cardiac events. Corteville ...

Introduction Atrial fibrillation (AF)-induced cardiomyopathy (AIC) is retrospectively defined after normalisation of left ...

Luís Beck-da-Silva, MD; Adolfo de Bold, PhD, FRSC; Ross A. Davies, MD, FRCPC; Benjamin J.W. Chow, MD, FRCPC; Terrence D. Ruddy, MD, FRCPC; Margaret Fraser, RN ...

CHICAGO -- Gene therapy for Danon disease, a rare inherited cause of hypertrophic cardiomyopathy, appeared to improve or ...

In this randomized controlled trial of patients with heart failure and mildly decreased or preserved ejection fraction, ...

Attruby (acoramidis), a near complete TTR stabilizer, has been approved by FDA to reduce cardiovascular death and ...

The chambers release peptide hormones, including ‘atrial natriuretic peptide’ and ‘brain natriuretic peptide’, which help regulate the balance of fluid in the body by affecting the kidneys.

Emerging research highlights the cardiovascular benefits of popular anti-obesity medications, such as GLP-1-based therapies.

The US Food and Drug Administration (FDA) has approved BridgeBio Pharma’s Attruby (acoramidis), an oral transthyretin (TTR) ...

According to this new report, the global cardiac biomarkers testing market is estimated to be valued at US$ 5.7 billion in the year 2028, growing at a CAGR of 8.5% in the period 2020 to 2028. Growth ...